Do gM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease?
IL-2 and GM-CSF could be used as a potential adjuvant for VP1 and had synergistic effect when co-expressed or mixed with VP1.
In the present study, the influence of antiplatelet agents was different among age groups. The potential beneficial effects of antiplatelet agents must be weighed against their potential adverse effects in the context of SAH, considering the differences in age-related outcomes.